Literature DB >> 19685371

Nephrotoxicity associated with the use of intravenous colistin.

Cecilia Santamaría1, Analia Mykietiuk, Elena Temporiti, Martin E Stryjewski, Fabian Herrera, Pablo Bonvehi.   

Abstract

We retrospectively assessed the renal toxicity associated with the use of intravenous colistin. Fifty-four patients with multidrug-resistant Acinetobacter infections were included. At the end of therapy 6/54 patients (11%) suffered renal impairment. Renal impairment associated with the use of colistin is less frequent than initially reported.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19685371     DOI： 10.1080/00365540903147001

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  9 in total

1.  Colistin neurotoxicity: revisited.

Authors:  Aruna Nigam; Archana Kumari; Reena Jain; Swaraj Batra
Journal:  BMJ Case Rep       Date:  2015-07-23

2.  Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients.

Authors:  Marcelo M Mostardeiro; Carlos A P Pereira; Alexandre R Marra; Jose O M Pestana; Luis Fernando A Camargo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 3.  Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.

Authors:  Lauren M Lim; Neang Ly; Dana Anderson; Jenny C Yang; Laurie Macander; Anthony Jarkowski; Alan Forrest; Jurgen B Bulitta; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2010-12       Impact factor: 4.705

4.  Stability of colistimethate sodium in aqueous solution.

Authors:  A M Healan; W Gray; E J Fuchs; J M Griffiss; R A Salata; J Blumer
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

5.  Cell cycle arrest in a model of colistin nephrotoxicity.

Authors:  Michael T Eadon; Bradley K Hack; Jessy J Alexander; Chang Xu; M Eileen Dolan; Patrick N Cunningham
Journal:  Physiol Genomics       Date:  2013-08-06       Impact factor: 3.107

6.  Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.

Authors:  Wang Liang; Xiao-Fang Liu; Jun Huang; De-Mei Zhu; Jian Li; Jing Zhang
Journal:  BMC Infect Dis       Date:  2011-04-27       Impact factor: 3.090

7.  Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.

Authors:  Argyris S Michalopoulos; Matthew E Falagas
Journal:  Ann Intensive Care       Date:  2011-08-02       Impact factor: 6.925

8.  Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach.

Authors:  Michael T Eadon; Ronald J Hause; Amy L Stark; Ying-Hua Cheng; Heather E Wheeler; Kimberly S Burgess; Eric A Benson; Patrick N Cunningham; Robert L Bacallao; Pierre C Dagher; Todd C Skaar; M Eileen Dolan
Journal:  Int J Mol Sci       Date:  2017-03-18       Impact factor: 5.923

9.  Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia.

Authors:  Mirjana Lulic-Botica; Lilia Dejesus
Journal:  AJP Rep       Date:  2011-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.